. 2016 Jun 28;9:201–205. doi: 10.2147/DMSO.S99732

Table 2.

PDC in the first 6 months in patients with type 2 diabetes initiating therapy with either exenatide once weekly (n=5,449) or liraglutide once daily (n=24,648)

	Median PDC		PDC ≥0.80 (%)

	Exenatide once weekly	Liraglutide once daily	Exenatide once weekly	Liraglutide once daily
Total^a	0.88^* (0.47–1.00)^b	0.77^* (0.46–1.00)^b	53.4^*	48.1^*
Male	0.85^* (0.47–1.00)^b	0.77^* (0.49–1.00)^b	52.4^*	48.7^*
Female	0.86^* (0.47–1.00)^b	0.77^* (0.46–1.00)^b	52.0^*	47.5^*
Age groups
≤50 years	0.78^* (0.47–1.00)^b	0.77^* (0.45–1.00)^b	49.6^*	45.1^*
51–60 years	0.92^* (0.47–1.00)^b	0.79^* (0.53–1.00)^b	55.3^*	49.4^*
61–70 years	0.92^* (0.47–1.00)^b	0.79^* (0.46–1.00)^b	56.3^*	49.3^*
>70 years	0.81^* (0.47–1.00)^b	0.77^* (0.38–1.00)^b	50.6^*	44.6^*

Notes: LRx database, January 2011 to September 2014, Germany.

P<0.05: once-daily vs once-weekly GLP-1 RA.

Total includes male and female patients, as well as patients whose sex was not known.

25th, 75th percentiles.

Abbreviations: GLP-1 RA, glucagon-like peptide-1 receptor agonist; LRx, longitudinal prescriptions database; PDC, proportion of days covered.